Abstract:Introduction: Candida species are endowed with the ability to produce biofilms, which is one of the causes of pathogenicity, as biofilms protect yeasts from antifungal drugs. Candida glabrata ( Nakaseomyces glabrata ) is one of the most prevalent pathogenic yeasts in humans and a biofilm producer. Methods: The study was aimed at evaluating the combined effects of two highly promising antifungal biomolecules (AF 4 and AF 5 ) lipopeptide in nature, chromatographically purified to homogeneity from Bacillus subtilis ( B. subtilis ) and the standard antifungal fluconazole (at different concentrations) to demonstrate C. glabrata biofilm formation inhibition. Biofilm production and inhibition were evaluated by quantification of the biofilm biomass and metabolic activity using crystal violet (CV) staining and XTT reduction assays, respectively. Microscopic techniques such as confocal scanning laser microscopy (CSLM) and scanning electron microscopy (SEM) were employed to visualize biofilm formation and inhibition. Results and Discussion: Compared to untreated and fluconazole-treated biofilms, an enhanced in vitro anti-biofilm effect of the antifungal lipopeptides AF 4 /AF 5 alone and their combinations with fluconazole was established. The lipopeptides AF 4 /AF 5 alone at 8 and 16 μg/mL exhibited significant biomass and metabolic activity reductions. SEM and CSLM images provided evidence that the lipopeptide exposure results in architectural alterations and a significant reduction of C. glabrata biofilms, whereas (2′, 7′-dichlorofluorescin diacetate (DCFDA) and propidium iodide (PI) analyses showed reactive oxygen species (ROS) generation along with membrane permeabilization. The estimation of exopolysaccharides (EPS) in AF 4 /AF 5 -treated biofilms indicated EPS reduction. The combinations of fluconazole (64/128 μg/mL) and AF 4 /AF 5 lipopeptide (16 μg/mL) were found to significantly disrupt the mature (24 h) biofilms as revealed by CSLM and SEM studies. The CSLM images of biofilms were validated using COMSTAT. The FTIR-analyses indicate the antibiofilm effects of both lipopeptides on 24 h biofilms to support CSLM and SEM observations. The combinations of fluconazole (64/128 μg/mL) and AF 4 /AF 5 lipopeptide were found to disrupt the mature biofilms; the study also showed that the lipopeptides alone have the potentials to combat C. glabrata biofilms. Taken together, it may be suggested that these lipopeptide leads can be optimized to potentially apply on various surfaces to either reduce or nearly eradicate yeast biofilms.

Development of cream to enhance the antifungal activity and reduce the side effects of fluconazole for the treatment of Candida albicans

Fluconazole Microemulsions: Preparation, Statistical Optimization by Two-Level Factorial Design, and Physicochemical Evaluation

Augmentation of antifungal activity of fluconazole using a clove oil nanoemulgel formulation optimized by factorial randomized D-optimal design

Optimizing Mucoadhesive Film-Forming Spray for Efficient Oral Delivery of Fluconazole in Candidiasis Treatment

Carboxylic acid and phosphate ester derivatives of fluconazole: synthesis and antifungal activities

Optimizing fluconazole-embedded transfersomal gel for enhanced antifungal activity and compatibility studies

Topical delivery systems containing clotrimazole for the management of candidiasis: Effect of different excipients and enhanced antifungal activity of nanovesicles

Preparation of Fluconazole Nanoemulsion and Its Antifungal Activity in Vitro

Berberine-fluconazole microparticle-based combination therapy to treat candidiasis infections

ASLdC3: A Derivative of Acidic Sophorolipid Disrupts Mitochondrial Function, Induces ROS Generation, and Inhibits Biofilm Formation in Candida albicans

In Vitro, Ex Vivo, and In Vivo Evaluation of Nanoparticle-Based Topical Formulation Against Candida albicans Infection

Fluconazole-Loaded Ibuprofen In Situ Gel-Based Oral Spray for Oropharyngeal Candidiasis Treatment

DESIGN, FABRICATION, IN VITRO, AND EX-VIVO PERMEATION STUDY OF MICRO-EMULSIFIED HYDROGEL OF FLUCONAZOLE (MHG-FLCZ) USING A CENTRAL COMPOSITE DESIGN (CCD)

Revolutionizing treatment for topical fungal infections: evaluating penetration-enhancer-containing vesicles as a fluconazole delivery system: Ex-vivo and in-vivo dermal testing

Development and evaluation of an anti-candida cream based on silver nanoparticles

Synergistic Effect of the Combination of Deferoxamine and Fluconazole in Vitro and in Vivo Against Fluconazole-Resistant Candida Spp.

In Silico Guided Nanoformulation Strategy for Circumvention of Candida albicans Biofilm for Effective Therapy of Candidal Vulvovaginitis

Elucidating the structural basis for the enhanced antifungal activity of amide derivative against Candida albicans: a comprehensive computational investigation

Two promising Bacillus-derived antifungal lipopeptide leads AF4 and AF5 and their combined effect with fluconazole on the in vitro Candida glabrata biofilms

Novel nanoformulation for enhanced amphotericin B efficacy and sustained release using vetiver root cellulose nanofibers against Candida albicans

From Formulation Design for Bioavailability Improvement to Biocompatibility Testing and Antifungal Efficacy Evaluation